Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ANGLE plc
  6. Summary
    AGL   GB0034330679

ANGLE PLC

(AGL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
122.5(c) 122(c) 123(c) 125.5(c) 124(c) Last
258 673 134 062 208 795 174 895 619 751 Volume
+2.08% -0.41% +0.82% +2.03% -1.20% Change
More quotes
Estimated financial data (e)
Sales 2021 2,25 M 3,09 M 3,09 M
Net income 2021 -17,5 M -24,1 M -24,1 M
Net cash position 2021 29,6 M 40,7 M 40,7 M
P/E ratio 2021 -17,1x
Yield 2021 -
Sales 2022 5,21 M 7,16 M 7,16 M
Net income 2022 -21,4 M -29,4 M -29,4 M
Net cash position 2022 3,90 M 5,36 M 5,36 M
P/E ratio 2022 -13,6x
Yield 2022 -
Capitalization 291 M 401 M 400 M
EV / Sales 2021 116x
EV / Sales 2022 55,1x
Nbr of Employees -
Free-Float 85,3%
More Financials
Company
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a... 
More about the company
Ratings of ANGLE plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ANGLE PLC
09/30Angle Considers Nasdaq Listing to Support Growth Plans
CI
09/30PRESENTATION SLIDES 30 SEPTEMBER 202 : Interim Results for the six months ended 30 June 20..
PU
09/30ANGLE plc Reports Earnings Results for the Half Year Ended June 30, 2021
CI
09/27ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstrea..
CI
09/22ANGLE : Gets Supporting Evidence for Parsortix System Development from Spanish Study
MT
09/22Angle plc Announces That the Health Research Institute of Santiago
CI
08/09ANGLE plc Announces Institute of Oncology, Ljubljana, Slovenia Publishes Favourable Res..
CI
07/28ANGLE : Shares Jump 6% On Securing New Pharma Contract
MT
07/28Angle plc Agrees A Pharma Services Contract with Another New Customer for Its Recently ..
CI
07/09ANGLE plc Announces Published Results of a New Study Undertaken in Patients with Brain ..
CI
06/25FTSE 100 Set for Muted Start After BOE Decision
DJ
06/25ANGLE : Targets $28 Million Capital Raise To Fund Operational Expansion
MT
06/18ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung ..
CI
06/04ANGLE : Annual Report December 2020
PU
06/04ANGLE : Provides Additional Information to US FDA for Requested Clearance of Parsortix Sys..
MT
More news
News in other languages on ANGLE PLC
09/22Angle obtient des preuves de soutien au développement du système Parsortix grâce à une ..
More news
Chart ANGLE PLC
Duration : Period :
ANGLE plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANGLE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 124,00 GBX
Average target price 175,00 GBX
Spread / Average Target 41,1%
EPS Revisions
Managers and Directors
Andrew D. W. Newland Chief Executive Officer & Executive Director
Ian Francis Griffiths CFO, Secretary & Executive Director
Garth Robert Selvey Non-Executive Chairman
Craig M. Miller Clinical Studies Director
Brian Howlett Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ANGLE PLC159.69%401
SARTORIUS AG68.12%43 908
BIOTAGE AB (PUBL)72.81%1 819
REVENIO GROUP OYJ13.32%1 757
CELLAVISION AB (PUBL)31.73%1 120
VAREX IMAGING CORPORATION59.53%1 049